Lutein Supplementation in Healthy Children

Overview

This is a single site, randomized, double-blind placebo controlled parallel arm study assessing the effects of 6 months lutein supplementation on cognitive and visual outcomes in healthy children exposed to excessive digital screen time.

Full Title of Study: “Effects of Lutein Supplementation on Cognition and Vision in Healthy Children With Screen Time Exposure: A Randomized Controlled Trial”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: March 2024

Detailed Description

Studies in humans and primates have also shown that appropriate daily intake of lutein provides protection to the eyes from blue light from screen time devices such as computers, televisions and phones. It has been well-documented that children are spending far over the recommended two hours screen time per day and excessive exposure to the high energy blue light associated with digital devices has been shown to cause both short-term and long-term visual damage as well as disruption to the sleep cycle. With a globally aging population, if this deficit is not addressed adequately early on in life then there will be substantial public health consequences. A recent study predicted that if individuals were to consume the recommended levels of lutein and zeaxanthin daily, there would be a seven percent reduced risk for age related eye disease and a potential savings of over five billion US dollars annually.

Interventions

  • Dietary Supplement: lutein
    • daily dose of 5 mg lutein
  • Dietary Supplement: placebo
    • daily dose of 0 mg lutein

Arms, Groups and Cohorts

  • Experimental: Lutein
    • 5 mg lutein gummy taken daily for 180 days
  • Placebo Comparator: Placebo
    • 0 mg lutein gummy taken daily for 180 days

Clinical Trial Outcome Measures

Primary Measures

  • Macular Pigment Optical Density – heterochromatic flicker photometry
    • Time Frame: 6 months
    • Level of macular carotenoids deposited in the eye measured using the psychophysical technique of heterochromatic flicker photometry (QuantifEye MPS-II Device). Minimum score of 0, no maximum. Average values range from 0.0 to 1.0. Higher numbers represent greater macular pigment.
  • Macular Pigment Optical Density – haidinger’s brushes
    • Time Frame: 6 months
    • Level of macular carotenoids deposited in the eye measured using haidinger’s brushes (Azul Optics MP-Eye Device). Minimum score of 0, maximum score of 10. Higher values represent greater macular pigment.

Secondary Measures

  • Digital Eye strain change from baseline
    • Time Frame: 6 months
    • Visual Fatigue Scale total score. Minimum score of 6, Maximum score of 24. Higher scores indicate higher levels of digital eye strain. Benedetto, S., Drai-Zerbib, V., Pedrotti, M., Tissier, G., & Baccino, T. (2013). E-readers and visual fatigue. PLoS One, 8(12)
  • Sleep score change from baseline
    • Time Frame: 6 months
    • Total score on the Cleveland Adolescent Sleepiness Questionnaire. Minimum score of 16, Maximum score of 80. Higher scores indicate greater sleepiness. Spilsbury, J. C., et al. (2007). “The Cleveland adolescent sleepiness questionnaire: a new measure to assess excessive daytime sleepiness in adolescents.” J Clin Sleep Med 3(6): 603-612.
  • Verbal Fluency
    • Time Frame: 6 months
    • Letter and semantic fluency using letter and animal naming. Total number of words names in a 60 second time frame. Higher score indicates greater verbal fluency

Participating in This Clinical Trial

Inclusion Criteria

  • Age of 8 to 16 years – guardian-reported general good health – guardian-reported 4 hours or more of digital screen time daily Exclusion Criteria:

  • Currently using a supplement containing lutein or zeaxanthin

Gender Eligibility: All

Minimum Age: 8 Years

Maximum Age: 16 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Northcentral University
  • Provider of Information About this Clinical Study
    • Principal Investigator: Brenda Fonseca, Principal Investigator – Northcentral University
  • Overall Official(s)
    • Patrick McNamara, PhD, Study Chair, Northcentral University

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.